Not a Member?
Email this page
Send the page ""
to a friend, relative, colleague or yourself.
Separate multiple email address with a comma
We do not record any personal information entered above.
Thank you. Your email has been sent.
Enroll today in the free PDR Pharmacy Discount Card Program and help your patients save
Treatment of pain and inflammation associated with cataract surgery.
Adults: 1 drop to the affected eye qd, beginning 1 day prior to cataract surgery, continued on the day of surgery, and through the first 2 weeks of postoperative period. Administer additional drop 30-120 min prior to surgery. With Other Topical Ophthalmic Medications: Administer at least 5 min apart.
Pediatrics: ≥10 yrs: 1 drop to the affected eye qd, beginning 1 day prior to cataract surgery, continued on the day of surgery, and through the first 2 weeks of postoperative period. Administer additional drop 30-120 min prior to surgery. With Other Topical Ophthalmic Medications: Administer at least 5 min apart.
Sus: 0.3% [1.7mL]
Potential for increased bleeding time due to interference with thrombocyte aggregation. Increased bleeding of ocular tissues (eg, hyphemas) reported in conjunction with ocular surgery; caution with known bleeding tendencies. May slow or delay healing, or result in keratitis. Continued use may result in sight threatening epithelial breakdown, corneal thinning/erosion/ulceration/perforation; d/c if evidence of corneal epithelial breakdown occurs and monitor for corneal health. Caution with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus (DM), ocular surface diseases (eg, dry eye syndrome), rheumatoid arthritis (RA), or repeat ocular surgeries within a short period of time. Use >1 day prior to surgery or beyond 14 days post-surgery may increase risk and severity of corneal adverse events. Avoid use with contact lenses and during late pregnancy.
Capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure, sticky sensation, conjunctival edema, corneal edema, dry eye, lid margin crusting, ocular discomfort, ocular hyperemia/pain/pruritus, photophobia, tearing, vitreous detachment.
May increase potential for healing problems with topical steroids. Caution with agents that may prolong bleeding time.
Category C, caution in nursing.
NSAID; thought to inhibit the action of prostaglandin H synthase (cyclooxygenase), an enzyme required for prostaglandin production.
Absorption: Cmax=0.847ng/mL (nepafenac), 1.13ng/mL (amfenac); Tmax=0.5 hr (nepafenac), 0.75 hr (amfenac). Metabolism: Hydrolysis via ocular tissue hydrolases to amfenac (metabolite).
Assess for previous hypersensitivity to the drug, bleeding tendencies, complicated or repeated ocular surgeries, corneal denervation, corneal epithelial defects, DM, ocular surface diseases, RA, contact lens use, pregnancy/nursing status, and possible drug interactions.
Monitor for hypersensitivity reactions, wound healing problems, keratitis, increased bleeding time, bleeding of ocular tissues in conjunction with ocular surgery, epithelial breakdown, corneal thinning/erosion/ulceration/perforation, and other adverse reactions.
Inform of possibility that slow or delayed healing may occur. Instruct to avoid allowing the tip of the container to contact the eye or surrounding structures. Advise that use of the same bottle for both eyes is not recommended. Instruct not to use while wearing contact lens. Advise to notify physician if an intercurrent ocular condition (eg, trauma or infection) develops or if undergoing ocular surgery to assess continuation of therapy.
Administration: Ocular route. Shake well before use. Storage: 2-25°C (36-77°F). Protect from light.